Adherence to antiparkinson medication in a multicenter European study
Identifieur interne : 000A96 ( Main/Corpus ); précédent : 000A95; suivant : 000A97Adherence to antiparkinson medication in a multicenter European study
Auteurs : Donald Grosset ; Angelo Antonini ; Margherita Canesi ; Gianni Pezzoli ; Andrew Lees ; Karen Shaw ; Esther Cubo ; Pablo Martinez-Martin ; Olivier Rascol ; Laurence Negre-Pages ; Ana Senard ; Johannes Schwarz ; Karl Strecker ; Heinz Reichmann ; Alexander Storch ; Matthias Löhle ; Fabrizio Stocchi ; Katherine GrossetSource :
- Movement Disorders [ 0885-3185 ] ; 2009-04-30.
English descriptors
- KwdEn :
Abstract
Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22112
Links to Exploration step
ISTEX:40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adherence to antiparkinson medication in a multicenter European study</title><author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name><affiliation><mods:affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name><affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name><affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>University College London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Shaw, Karen" sort="Shaw, Karen" uniqKey="Shaw K" first="Karen" last="Shaw">Karen Shaw</name><affiliation><mods:affiliation>University College London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Cubo, Esther" sort="Cubo, Esther" uniqKey="Cubo E" first="Esther" last="Cubo">Esther Cubo</name><affiliation><mods:affiliation>Carlos III Institute for Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Carlos III Institute for Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Negre Ages, Laurence" sort="Negre Ages, Laurence" uniqKey="Negre Ages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name><affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Senard, Ana" sort="Senard, Ana" uniqKey="Senard A" first="Ana" last="Senard">Ana Senard</name><affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name><affiliation><mods:affiliation>University of Leipzig, Germany</mods:affiliation></affiliation></author><author><name sortKey="Strecker, Karl" sort="Strecker, Karl" uniqKey="Strecker K" first="Karl" last="Strecker">Karl Strecker</name><affiliation><mods:affiliation>University of Leipzig, Germany</mods:affiliation></affiliation></author><author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name><affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name><affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Lohle, Matthias" sort="Lohle, Matthias" uniqKey="Lohle M" first="Matthias" last="Löhle">Matthias Löhle</name><affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation><mods:affiliation>IRCCS San Raffaele Pisana, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Grosset, Katherine" sort="Grosset, Katherine" uniqKey="Grosset K" first="Katherine" last="Grosset">Katherine Grosset</name><affiliation><mods:affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22112</idno><idno type="url">https://api.istex.fr/document/40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A96</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Adherence to antiparkinson medication in a multicenter European study</title><author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name><affiliation><mods:affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name><affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name><affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>University College London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Shaw, Karen" sort="Shaw, Karen" uniqKey="Shaw K" first="Karen" last="Shaw">Karen Shaw</name><affiliation><mods:affiliation>University College London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Cubo, Esther" sort="Cubo, Esther" uniqKey="Cubo E" first="Esther" last="Cubo">Esther Cubo</name><affiliation><mods:affiliation>Carlos III Institute for Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Carlos III Institute for Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Negre Ages, Laurence" sort="Negre Ages, Laurence" uniqKey="Negre Ages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name><affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Senard, Ana" sort="Senard, Ana" uniqKey="Senard A" first="Ana" last="Senard">Ana Senard</name><affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name><affiliation><mods:affiliation>University of Leipzig, Germany</mods:affiliation></affiliation></author><author><name sortKey="Strecker, Karl" sort="Strecker, Karl" uniqKey="Strecker K" first="Karl" last="Strecker">Karl Strecker</name><affiliation><mods:affiliation>University of Leipzig, Germany</mods:affiliation></affiliation></author><author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name><affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name><affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Lohle, Matthias" sort="Lohle, Matthias" uniqKey="Lohle M" first="Matthias" last="Löhle">Matthias Löhle</name><affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation><mods:affiliation>IRCCS San Raffaele Pisana, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Grosset, Katherine" sort="Grosset, Katherine" uniqKey="Grosset K" first="Katherine" last="Grosset">Katherine Grosset</name><affiliation><mods:affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-04-30">2009-04-30</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="826">826</biblScope><biblScope unit="page" to="832">832</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7</idno><idno type="DOI">10.1002/mds.22112</idno><idno type="ArticleID">MDS22112</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>therapy adherence</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Donald Grosset MD</name><affiliations><json:string>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</json:string></affiliations></json:item><json:item><name>Angelo Antonini MD</name><affiliations><json:string>Parkinson Institute Milan, Italy</json:string></affiliations></json:item><json:item><name>Margherita Canesi MD</name><affiliations><json:string>Parkinson Institute Milan, Italy</json:string></affiliations></json:item><json:item><name>Gianni Pezzoli MD</name><affiliations><json:string>Parkinson Institute Milan, Italy</json:string></affiliations></json:item><json:item><name>Andrew Lees MD</name><affiliations><json:string>University College London, United Kingdom</json:string></affiliations></json:item><json:item><name>Karen Shaw RGN</name><affiliations><json:string>University College London, United Kingdom</json:string></affiliations></json:item><json:item><name>Esther Cubo MD</name><affiliations><json:string>Carlos III Institute for Health, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Pablo Martinez‐Martin MD</name><affiliations><json:string>Carlos III Institute for Health, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD</name><affiliations><json:string>Toulouse University Hospital, Toulouse, France</json:string></affiliations></json:item><json:item><name>Laurence Negre‐Pages MD</name><affiliations><json:string>Toulouse University Hospital, Toulouse, France</json:string></affiliations></json:item><json:item><name>Ana Senard MD</name><affiliations><json:string>Toulouse University Hospital, Toulouse, France</json:string></affiliations></json:item><json:item><name>Johannes Schwarz MD</name><affiliations><json:string>University of Leipzig, Germany</json:string></affiliations></json:item><json:item><name>Karl Strecker MD</name><affiliations><json:string>University of Leipzig, Germany</json:string></affiliations></json:item><json:item><name>Heinz Reichmann MD</name><affiliations><json:string>Technical University of Dresden, Germany</json:string></affiliations></json:item><json:item><name>Alexander Storch MD</name><affiliations><json:string>Technical University of Dresden, Germany</json:string></affiliations></json:item><json:item><name>Matthias Löhle MD</name><affiliations><json:string>Technical University of Dresden, Germany</json:string></affiliations></json:item><json:item><name>Fabrizio Stocchi MD</name><affiliations><json:string>IRCCS San Raffaele Pisana, Rome, Italy</json:string></affiliations></json:item><json:item><name>Katherine Grosset MD</name><affiliations><json:string>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>therapy adherence</value></json:item></subject><articleId><json:string>MDS22112</json:string></articleId><language><json:string>eng</json:string></language><abstract>Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P > 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>6.754</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>2</keywordCount><abstractCharCount>1812</abstractCharCount><pdfWordCount>3754</pdfWordCount><pdfCharCount>25613</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>262</abstractWordCount></qualityIndicators><title>Adherence to antiparkinson medication in a multicenter European study</title><genre><json:string>article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>832</last><first>826</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22112</json:string></doi><id>40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Adherence to antiparkinson medication in a multicenter European study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Adherence to antiparkinson medication in a multicenter European study</title><author><persName><forename type="first">Donald</forename><surname>Grosset</surname></persName><roleName type="degree">MD</roleName><affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</affiliation></author><author><persName><forename type="first">Angelo</forename><surname>Antonini</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute Milan, Italy</affiliation></author><author><persName><forename type="first">Margherita</forename><surname>Canesi</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute Milan, Italy</affiliation></author><author><persName><forename type="first">Gianni</forename><surname>Pezzoli</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute Milan, Italy</affiliation></author><author><persName><forename type="first">Andrew</forename><surname>Lees</surname></persName><roleName type="degree">MD</roleName><affiliation>University College London, United Kingdom</affiliation></author><author><persName><forename type="first">Karen</forename><surname>Shaw</surname></persName><roleName type="degree">RGN</roleName><affiliation>University College London, United Kingdom</affiliation></author><author><persName><forename type="first">Esther</forename><surname>Cubo</surname></persName><roleName type="degree">MD</roleName><affiliation>Carlos III Institute for Health, Madrid, Spain</affiliation></author><author><persName><forename type="first">Pablo</forename><surname>Martinez‐Martin</surname></persName><roleName type="degree">MD</roleName><affiliation>Carlos III Institute for Health, Madrid, Spain</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD</roleName><affiliation>Toulouse University Hospital, Toulouse, France</affiliation></author><author><persName><forename type="first">Laurence</forename><surname>Negre‐Pages</surname></persName><roleName type="degree">MD</roleName><affiliation>Toulouse University Hospital, Toulouse, France</affiliation></author><author><persName><forename type="first">Ana</forename><surname>Senard</surname></persName><roleName type="degree">MD</roleName><affiliation>Toulouse University Hospital, Toulouse, France</affiliation></author><author><persName><forename type="first">Johannes</forename><surname>Schwarz</surname></persName><roleName type="degree">MD</roleName><affiliation>University of Leipzig, Germany</affiliation></author><author><persName><forename type="first">Karl</forename><surname>Strecker</surname></persName><roleName type="degree">MD</roleName><affiliation>University of Leipzig, Germany</affiliation></author><author><persName><forename type="first">Heinz</forename><surname>Reichmann</surname></persName><roleName type="degree">MD</roleName><affiliation>Technical University of Dresden, Germany</affiliation></author><author><persName><forename type="first">Alexander</forename><surname>Storch</surname></persName><roleName type="degree">MD</roleName><affiliation>Technical University of Dresden, Germany</affiliation></author><author><persName><forename type="first">Matthias</forename><surname>Löhle</surname></persName><roleName type="degree">MD</roleName><affiliation>Technical University of Dresden, Germany</affiliation></author><author><persName><forename type="first">Fabrizio</forename><surname>Stocchi</surname></persName><roleName type="degree">MD</roleName><affiliation>IRCCS San Raffaele Pisana, Rome, Italy</affiliation></author><author><persName><forename type="first">Katherine</forename><surname>Grosset</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Southern General Hospital, Glasgow, United Kingdom</p></note><affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-04-30"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="826">826</biblScope><biblScope unit="page" to="832">832</biblScope></imprint></monogr><idno type="istex">40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7</idno><idno type="DOI">10.1002/mds.22112</idno><idno type="ArticleID">MDS22112</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>therapy adherence</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-01-28">Received</change><change when="2008-04-05">Registration</change><change when="2009-04-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/mds.v24:6</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2009-04-30">30 April 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="50" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22112</doi><idGroup><id type="unit" value="MDS22112"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-01-28"></event><event type="manuscriptRevised" date="2008-04-02"></event><event type="manuscriptAccepted" date="2008-04-05"></event><event type="publishedOnlineEarlyUnpaginated" date="2009-02-03"></event><event type="firstOnline" date="2009-02-03"></event><event type="publishedOnlineFinalForm" date="2009-04-24"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-04-20"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">826</numbering><numbering type="pageLast">832</numbering></numberingGroup><correspondenceTo>Southern General Hospital, Glasgow, United Kingdom</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22112.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="20"></count><count type="wordTotal" number="5265"></count></countGroup><titleGroup><title type="main" xml:lang="en">Adherence to antiparkinson medication in a multicenter European study</title><title type="short" xml:lang="en">Adherence to Antiparkinson Medication</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Donald</givenNames><familyName>Grosset</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Angelo</givenNames><familyName>Antonini</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Margherita</givenNames><familyName>Canesi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Gianni</givenNames><familyName>Pezzoli</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Andrew</givenNames><familyName>Lees</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Karen</givenNames><familyName>Shaw</familyName><degrees>RGN</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Esther</givenNames><familyName>Cubo</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Pablo</givenNames><familyName>Martinez‐Martin</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Laurence</givenNames><familyName>Negre‐Pages</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Ana</givenNames><familyName>Senard</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Johannes</givenNames><familyName>Schwarz</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Karl</givenNames><familyName>Strecker</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Heinz</givenNames><familyName>Reichmann</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au15" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Alexander</givenNames><familyName>Storch</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au16" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Matthias</givenNames><familyName>Löhle</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au17" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Fabrizio</givenNames><familyName>Stocchi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au18" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Katherine</givenNames><familyName>Grosset</familyName><degrees>MD</degrees></personName><contactDetails><email>kgrosset@nhs.net</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>Parkinson Institute Milan, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="GB" type="organization"><unparsedAffiliation>University College London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="ES" type="organization"><unparsedAffiliation>Carlos III Institute for Health, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Toulouse University Hospital, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="DE" type="organization"><unparsedAffiliation>University of Leipzig, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="DE" type="organization"><unparsedAffiliation>Technical University of Dresden, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="IT" type="organization"><unparsedAffiliation>IRCCS San Raffaele Pisana, Rome, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">therapy adherence</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (<i>P</i> = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (<i>P</i> = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), <i>P</i> = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (<i>P</i> < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Adherence to antiparkinson medication in a multicenter European study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Adherence to Antiparkinson Medication</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Adherence to antiparkinson medication in a multicenter European study</title></titleInfo><name type="personal"><namePart type="given">Donald</namePart><namePart type="family">Grosset</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Angelo</namePart><namePart type="family">Antonini</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Margherita</namePart><namePart type="family">Canesi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gianni</namePart><namePart type="family">Pezzoli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Lees</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University College London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karen</namePart><namePart type="family">Shaw</namePart><namePart type="termsOfAddress">RGN</namePart><affiliation>University College London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Esther</namePart><namePart type="family">Cubo</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Carlos III Institute for Health, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pablo</namePart><namePart type="family">Martinez‐Martin</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Carlos III Institute for Health, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Toulouse University Hospital, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laurence</namePart><namePart type="family">Negre‐Pages</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Toulouse University Hospital, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ana</namePart><namePart type="family">Senard</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Toulouse University Hospital, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Johannes</namePart><namePart type="family">Schwarz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University of Leipzig, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karl</namePart><namePart type="family">Strecker</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University of Leipzig, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Heinz</namePart><namePart type="family">Reichmann</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Technical University of Dresden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexander</namePart><namePart type="family">Storch</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Technical University of Dresden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Matthias</namePart><namePart type="family">Löhle</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Technical University of Dresden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabrizio</namePart><namePart type="family">Stocchi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>IRCCS San Raffaele Pisana, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Katherine</namePart><namePart type="family">Grosset</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</affiliation><description>Correspondence: Southern General Hospital, Glasgow, United Kingdom</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-04-30</dateIssued><dateCaptured encoding="w3cdtf">2008-01-28</dateCaptured><dateValid encoding="w3cdtf">2008-04-05</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">3</extent><extent unit="references">20</extent><extent unit="words">5265</extent></physicalDescription><abstract lang="en">Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>therapy adherence</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>826</start><end>832</end><total>7</total></extent></part></relatedItem><identifier type="istex">40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7</identifier><identifier type="DOI">10.1002/mds.22112</identifier><identifier type="ArticleID">MDS22112</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000A96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7
|texte= Adherence to antiparkinson medication in a multicenter European study
}}
| This area was generated with Dilib version V0.6.23. |  |